Salute e Benessere

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – May 5, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 4, 2026, from Atlas Special Opportunities II, LLC…
Actusnews Wire
05/05/2026

OXURION : Publication Annual Report - Annual Shareholders Meeting

Leuven, BELGIUM – April 30, 2026 – 18:30 PM CET - Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, has today published its annual report for the financial year 2025. The annual report for the year ending December 31, 2025 is available in the “Investors” section of the Company's website and can also be…
Actusnews Wire
30/04/2026

THERANEXUS : THX Pharma Publishes Its 2025 Annual Results, Cash Position as of…

Lyon, France – April 28, 2026 – 7:00 p.m. CEST – THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces its annual results as of December 31, 2025, its cash position as of March 31, 2026, and provides a business update…
Actusnews Wire
28/04/2026

LUMIBIRD: Q1 REVENUE UP +0.7% AND +4.1% AT CONSTANT EXCHANGE RATES

Lannion, 27 April 2026– 5:45 pm Q1 revenue up +0.7% and +4.1% at constant exchange rates The LUMIBIRD Group (FR0000038242 - LBIRD), the European leader in laser technologies, reported a 0.7% increase (+4.1% at constant exchange rates and scope) in its consolidated revenue for the first quarter of 2026, reaching €49.7 million…
Actusnews Wire
27/04/2026

Klea Holding reports record results in 2025 and demonstrates remarkable…

Annual revenue growth of 28%, to €22.2 million. 57% increase in EBITDA and normalized EBITDA, representing a margin of 31%. Operating income doubled to €3.4 million. Net income attributable to the Group positive for the second consecutive year at €2.3 million. Cash position of over €5 million and net financial debt close to zero…
Actusnews Wire
23/04/2026

DMS GROUP : Q1 2026 REVENUE: EUR 10 MILLION

Q1 2026 REVENUE: €10 MILLION Cyclical slowdown in activity in Q1 2026 - Recovery in growth expected in Q2 2026 Confirmation of the annual outlook: outperforming the medical imaging market by achieving another year of growth in activity in a market temporarily impacted by the global context April 21, 2026 – 5:45 pm – Diagnostic Medical Systems…
Actusnews Wire
21/04/2026

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – April 16, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 16, 2026, from Atlas Special Opportunities II…
Actusnews Wire
16/04/2026

DMS GROUP : FURTHER STRONG GROWTH IN ANNUAL RESULTS FOR THE 2025 FINANCIAL YEAR

FURTHER STRONG GROWTH IN ANNUAL RESULTS FOR THE 2025 FINANCIAL YEAR Solid growth in activity of +8.5% in 2025 to €50 million, driven by sustained international development and the North American market Dynamic EBITDA growth of +69% - EBITDA margin of 9.1% (vs. 5.9%), of which 11.0% in H2 2025 +€2.8 million improvement in net income, now positive…
Actusnews Wire
14/04/2026

LUMIBIRD MEDICAL ACCELERATES ASIA PACIFIC EXPANSION WITH FUTURE ACQUISITION OF…

Lannion, 8 April 2026 – 5:45 pm LUMIBIRD MEDICAL ACCELERATES ASIA PACIFIC EXPANSION WITH FUTURE ACQUISITION OF BIZ MEDIC SDN BHD TO FORM NEW SOUTHEAST ASIAN HUB The LUMIBIRD Group (FR0000038242 – LBIRD), the European leader in laser technologies, announces that its subsidiary Lumibird Medical has signed an agreement to acquire its long-term…
Actusnews Wire
08/04/2026

DMS GROUP OBTAINS EUROPEAN MDR CERTIFICATION FOR ITS STRATOS BONE DENSITOMETER…

April 7, 2026 – 6:00 pm – Diagnostic Medical Systems (Euronext Growth Paris: FR0012202497 – ALDMS), a specialist in high-performance medical imaging systems for digital radiology and bone densitometry, announces that it has obtained MDR (Medical Device Regulation – Regulation (EU) 2017/745) certification for its entire range of bone densitometers, STRATOS and STRATOS DR…
Actusnews Wire
07/04/2026

OXURION : Postponement Annual Shareholders Meeting

Leuven, BELGIUM – April 7, 2026 – 18:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, today made the following announcement regarding the financial calendar: Due to administrative reasons, the annual accounts of the Company have not been finalized yet…
Actusnews Wire
07/04/2026

Klea Holding is accelerating its diversification into the healthcare sector with…

Paris, 1 April 2026 KLEA HOLDING (FR0013481835 – ALKLH), a group specialising in the acquisition, development and digitalisation of businesses across various sectors, announces the creation of Klea Pharmaceuticals, a new company set up to market a portfolio of licensed medicines in high-growth markets across the Middle East and Africa…
Actusnews Wire
01/04/2026

DMS GROUP: THE EUROPEAN INVESTMENT BANK GRANTS A FINANCING LINE OF UP TO EUR 20…

Funding with the support of the European Union, through InvestEU, to accelerate the development of the new generation of medical imaging solutions as part of the next strategic plan #Imaging 2030 with the ambition to make DMS Group a European leader in medical imaging on the world stage. The financing is part of EIB's strong commitment to health…
Actusnews Wire
27/03/2026

THERANEXUS : THX Pharma Announces the Publication of its Letter to Shareholders

Lyon, France – March 25, 2026, 6:30 pm CET – THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of its letter to shareholders. To download the newsletter, click here. This letter is also available on the Theranexus website (link), in the…
Actusnews Wire
25/03/2026

Oxurion signs a letter of intent for the acquisition of an international CRO

Leuven, BELGIUM – March 19, 2026 – 18:30 PM CET - Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, announces the signing of a letter of intent (LOI) for the acquisition of a majority stake in an international CRO operating in Europe, North Africa, and the Middle East…
Actusnews Wire
19/03/2026

Oxurion ondertekent een intentieverklaring voor de overname van een…

Leuven, BELGIË – 19 maart 2026 – 18u30 CET Oxurion NV (Euronext Brussel: OXUR), een farmaceutische onderaannemingsvennootschap gevestigd in Leuven, kondigt de ondertekening aan van een intentieverklaring (LOI) voor de overname van een meerderheidsbelang in een internationale CRO die actief is in Europa, Noord-Afrika en het Midden-Oosten…
Actusnews Wire
19/03/2026

BASTIDE : 2025-2026 half-year results

Recurring operating margin: 9.0%, in line with the annual target Operating profit up 12.5% Operating free cash flow: €24.3 million, a threefold increase in one year Significant improvement in leverage: 2.77x at December 31, 2025 (vs 3.41x at June 30, 2025) 2025-2026 outlook confirmed Caissargues, March 18, 2026 – Groupe Bastide, a leading European…
Actusnews Wire
18/03/2026

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – March 18, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on March 17, 2026, from Atlas Special Opportunities II…
Actusnews Wire
18/03/2026

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1]. Leuven, BELGIUM – March 16 2026 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of…
Actusnews Wire
16/03/2026

ATON: UPDATE ON THE ACTIVITIES OF ITS SUBSIDIARY INOVIEM SCIENTIFIC

Illkirch, March 11th 2026 – 18h00 Aton Group (Euronext Growth Paris – FR0004153930 – ALTAO), a life sciences and medtech investment holding, provides an update on the operational activities of its subsidiary Inoviem Scientific (the “Company”), a translational pharmacology company. Inoviem Scientific is reimagining drug development and deployment by…
Actusnews Wire
11/03/2026

Oxurion verlengt haar financieringsprogramma

Leuven, BELGIË – 10 maart 2026 – 18u30 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdzetel in Leuven, kondigt de ondertekening aan van een vierde amendement op haar converteerbare obligatie-intekeningsovereenkomst met Atlas Special Opportunities II, LLC. Dit amendement verlengt het totale financieringsprogramma met…
Actusnews Wire
10/03/2026

Oxurion Extends Its Financing Program

Leuven, BELGIUM – March 10, 2026 – 06:30 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a fourth amendment to its convertible bond subscription agreement with Atlas Special Opportunities II, LLC. This amendment extends the overall financing program by an additional 12…
Actusnews Wire
10/03/2026

LUMIBIRD : 2025 ANNUAL RESULTS SHOW STRONG GROWTH

Lannion, 10/03/2026 – 5:45 pm 2025 annual results show strong growth EBITDA margin(1) of 20.2%, up +4.3 points Free cash flow of €13.1 million Implementation of a dividend distribution The Lumibird Group, European leader in laser technologies, recorded strong growth in its results in 2025, with EBITDA of €45.6 million, up +38% and representing 20…
Actusnews Wire
10/03/2026

Oxurion bevestigt voortzetting van de besprekingen over haar voorgenomen…

Leuven, BELGIUM– 27 februari 2026 – 18u00 CET –Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, kondigt de verlenging aan van de onderhandelingen met betrekking tot de voorgenomen verwerving van een meerderheidsbelang in een Franse CRO, zoals aangekondigd op 13 oktober 2025…
Actusnews Wire
27/02/2026
Altri  Comunicati